Eikon Therapeutics, Inc. (NASDAQ:EIKN) Receives Average Recommendation of “Hold” from Brokerages

Shares of Eikon Therapeutics, Inc. (NASDAQ:EIKN) have received a consensus rating of “Hold” from the eight research firms that are currently covering the firm, MarketBeat reports. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating on the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $25.20.

A number of equities research analysts have weighed in on the company. Zacks Research upgraded Eikon Therapeutics to a “hold” rating in a research report on Friday, February 27th. Mizuho assumed coverage on Eikon Therapeutics in a research report on Monday, March 2nd. They set an “outperform” rating and a $26.00 price objective for the company. Weiss Ratings assumed coverage on Eikon Therapeutics in a research report on Monday, June 1st. They set a “sell (e-)” rating for the company. Cantor Fitzgerald reiterated an “overweight” rating on shares of Eikon Therapeutics in a research report on Tuesday, June 2nd. Finally, Morgan Stanley assumed coverage on Eikon Therapeutics in a research report on Monday, March 2nd. They set an “overweight” rating and a $32.00 price objective for the company.

Eikon Therapeutics Price Performance

NASDAQ:EIKN opened at $8.77 on Wednesday. The company’s 50 day moving average is $10.30. Eikon Therapeutics has a 52 week low of $7.90 and a 52 week high of $17.40.

Eikon Therapeutics (NASDAQ:EIKN) last issued its quarterly earnings data on Monday, March 30th. The company reported ($26.23) earnings per share (EPS) for the quarter.

Eikon Therapeutics Company Profile

We are a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing important, innovative medicines to address serious unmet medical needs. We are led by world-renowned drug developers Dr. Roger M. Perlmutter, M.D., Ph.D., and Dr. Roy Baynes, M.D., Ph.D. Our vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. Our initial focus is oncology, where we are advancing a pipeline of drug candidates targeting areas of high unmet need in large indications.